These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16652149)

  • 1. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
    Zheng R; Iwase A; Shen R; Goodman OB; Sugimoto N; Takuwa Y; Lerner DJ; Nanus DM
    Oncogene; 2006 Sep; 25(44):5942-52. PubMed ID: 16652149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.
    Sumitomo M; Milowsky MI; Shen R; Navarro D; Dai J; Asano T; Hayakawa M; Nanus DM
    Cancer Res; 2001 Apr; 61(8):3294-8. PubMed ID: 11309283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells.
    Ying Z; Jin L; Palmer T; Webb RC
    Mol Pharmacol; 2006 Mar; 69(3):932-40. PubMed ID: 16354763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bombesin stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-dependent manner.
    Saurin JC; Fallavier M; Sordat B; Gevrey JC; Chayvialle JA; Abello J
    Cancer Res; 2002 Aug; 62(16):4829-35. PubMed ID: 12183443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.
    Sumitomo M; Shen R; Goldberg JS; Dai J; Navarro D; Nanus DM
    Cancer Res; 2000 Dec; 60(23):6590-6. PubMed ID: 11118039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells.
    Greenberg DL; Mize GJ; Takayama TK
    Biochemistry; 2003 Jan; 42(3):702-9. PubMed ID: 12534282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
    Sumitomo M; Shen R; Walburg M; Dai J; Geng Y; Navarro D; Boileau G; Papandreou CN; Giancotti FG; Knudsen B; Nanus DM
    J Clin Invest; 2000 Dec; 106(11):1399-407. PubMed ID: 11104793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for Lsc/p115 RhoGEF and LARG in regulating RhoA activity downstream of adhesion to fibronectin.
    Dubash AD; Wennerberg K; García-Mata R; Menold MM; Arthur WT; Burridge K
    J Cell Sci; 2007 Nov; 120(Pt 22):3989-98. PubMed ID: 17971419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism.
    Hamadmad SN; Hohl RJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1227-33. PubMed ID: 18079357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells.
    Loberg RD; Tantivejkul K; Craig M; Neeley CK; Pienta KJ
    J Cell Biochem; 2007 Aug; 101(5):1292-300. PubMed ID: 17492768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility.
    Chang YW; Marlin JW; Chance TW; Jakobi R
    Cancer Res; 2006 Dec; 66(24):11700-8. PubMed ID: 17178865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal peptide signalling in health and disease.
    Rozengurt E; Guha S; Sinnett-Smith J
    Eur J Surg Suppl; 2002; (587):23-38. PubMed ID: 16144198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
    Horiguchi A; Zheng R; Goodman OB; Shen R; Guan H; Hersh LB; Nanus DM
    Cancer Gene Ther; 2007 Jun; 14(6):583-9. PubMed ID: 17415380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
    Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
    Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galpha 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF.
    Suzuki N; Nakamura S; Mano H; Kozasa T
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):733-8. PubMed ID: 12515866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
    Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
    Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modular architecture and novel protein-protein interactions regulating the RGS-containing Rho guanine nucleotide exchange factors.
    Vázquez-Prado J; Basile J; Gutkind JS
    Methods Enzymol; 2004; 390():259-85. PubMed ID: 15488183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
    Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
    Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.
    Bartolomé RA; Wright N; Molina-Ortiz I; Sánchez-Luque FJ; Teixidó J
    Cancer Res; 2008 Oct; 68(20):8221-30. PubMed ID: 18922893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.